Clareo Health | The Biomarker Exploratory Study in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Chugai Pharmaceutical
With
Japan Lung Cancer Society
Age
20–any
Sex
ALL
Healthy volunteers
Not accepted
You may not be if
\<non-small cell lung cancer cohort\>
1. Patients 20 years of age or older at the time of signed consent.
2. Patients with unresectable, advanced and recurrent non-small cell lung cancer.
3. Patients who are scheduled to start atezolizumab combination therapy in clinical practice, based on the atezolizumab package insert and the Optimal Clinical Use Guideline.
4. Patients who signed informed consent form before enrolling the study. The consent from a legally acceptable representative is required for the patients with uncertain capacity of judgments.
\<extensive disease small cell lung cancer cohort\>
1. Patients 20 years of age or older at the time of signed consent.
2. Patients with extensive disease small cell lung cancer.
3. Patients who are scheduled to start atezolizumab combination therapy in clinical practice, based on the atezolizumab package insert and the Optimal Clinical Use Guideline.
4. Patients who signed informed consent form before enrolling the study. The consent from a legally acceptable representative is required for the patients with uncertain capacity of judgments. However, the samples of dead cases can be used for the analysis of immune microenvironment of small cell lung cancer by disclosing information on this study.
\<non-small cell lung cancer cohort\>
1\. Patients who are unsuitable for enrolment into the study by the investigator's judgment.
\<extensive disease small cell lung cancer cohort\>
1\. Patients who are unsuitable for enrolment into the study by the investigator's judgment.
